Latest Breaking News On - Jakob lindberg - Page 2 : comparemela.com

Oncopeptides provides update on Pepaxto US marketing authorization

/PRNewswire/ Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat.

United kingdomRolf gulliksenJakob lindbergEuropean unionDrug administrationEuropean medicines agencyGlobal head of corporate communicationsHealthcare products regulatory agencyKiller engagersGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capNasdaq stockholmOncopeptides ab

Oncopeptides AB: Oncopeptides provides update on Pepaxto US marketing authorization

STOCKHOLM, Dec. 7, 2022 /PRNewswire/ Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological

United kingdomRolf gulliksenJakob lindbergEuropean unionDrug administrationEuropean medicines agencyGlobal head of corporate communicationsHealthcare products regulatory agencyKiller engagersGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capNasdaq stockholm

Oncopeptides AB: Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

STOCKHOLM, Nov. 25, 2022 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investment

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investment

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investment